Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportMolecular Imaging: Non-radioactive/Multimodal Imaging: Clinical Applications of Non-radioactive/Multimodal Imaging

Assessment of treatment response with diffusion-weighted MRI and ADC in metastatic GIST as compared to 18F-FDG PET/CT: A pilot study

Vincent Dunet, Mélanie Koehli, Michael Montemurro, Serge Leyvraz, R. Meuli, S. Schmidt and John Prior
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 1002;
Vincent Dunet
1Nuclear Medicine, CHUV, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mélanie Koehli
2Radiology, CHUV, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Montemurro
3Oncology, CHUV, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Serge Leyvraz
3Oncology, CHUV, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Meuli
2Radiology, CHUV, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Schmidt
2Radiology, CHUV, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Prior
1Nuclear Medicine, CHUV, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1002

Objectives To evaluate the potential of diffusion-weighted MR imaging (DWI) with apparent diffusion coefficient (ADC) mapping for the assessment of gastrointestinal stromal tumor (GIST) response to targeted therapy in comparison with 18F-FDG PET/CT.

Methods Five patients (3W/2M, aged 56.4±13.4y) with a metastatic GIST underwent a 18F-FDG PET/CT (Discovery LS, GEMS) and a MRI (VIBE T1Gd, DWI [b=50,300,600] with ADC mapping) within 3.6±4d of each other, before and 4.2±2.9months (2-9 months) after a targeted therapy change. MRI and PET/CT studies were first analyzed blindly, before PET/CT images were coregistered to T1Gd-MR images for lesion detection. SUVmax and ADC were measured for the six largest lesions on MR. Changes in SUVmax and ADC values before and after therapy modification were analyzed with paired t-test and Spearman’s correlation.

Results Altogether, 24 lesions (15 hepatic and 9 non-hepatic) were analyzed on PET/CT and MR-images. Three small lesions (12.5%) were not detected on ADC maps and 4 lesions on the second PET/CT were excluded because of hepatic vascular activity. All lesions together, SUVmax decreased from 7.2±7.7g/mL to 5.9±5.9g/mL (mean difference -1.6±2.8g/mL, range -7 to 3g/mL, P=0.53) and ADC increased from (1.2±0.4)x10-3mm2/s to (1.4±0.4)x10-3mm2/s (difference (0.2±0.4)x10-3mm2/s, range (-0.4 to 0.9)x10-3mm2/s, P=0.07). Changes in SUVmax and ADC were significant for non-hepatic lesions (P=0.01 and P=0.003), but not for hepatic lesions (P=0.6 and P=0.3). Moreover, there was a significant association between SUVmax decrease and ADC increase (ρ=-0.64, P=0.004).

Conclusions Changes in ADC maps from diffusion-weighted MRI seem to reflect response of 18F-FDG-avid GIST to targeted therapy. Thus, DWI might be of interest for the assessment of targeted therapy response in GIST patients, but its exact diagnostic value needs to be investigated, as well as the effect of lesion size and time under-therapy before imaging

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 51, Issue supplement 2
May 2010
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Assessment of treatment response with diffusion-weighted MRI and ADC in metastatic GIST as compared to 18F-FDG PET/CT: A pilot study
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Assessment of treatment response with diffusion-weighted MRI and ADC in metastatic GIST as compared to 18F-FDG PET/CT: A pilot study
Vincent Dunet, Mélanie Koehli, Michael Montemurro, Serge Leyvraz, R. Meuli, S. Schmidt, John Prior
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 1002;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Assessment of treatment response with diffusion-weighted MRI and ADC in metastatic GIST as compared to 18F-FDG PET/CT: A pilot study
Vincent Dunet, Mélanie Koehli, Michael Montemurro, Serge Leyvraz, R. Meuli, S. Schmidt, John Prior
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 1002;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Imaging: Non-radioactive/Multimodal Imaging: Clinical Applications of Non-radioactive/Multimodal Imaging

  • Effectiveness of an image response assessment team (IRAT) approach to advance imaging biomarker inclusion in cancer therapy trials
  • Simultaneous PET/MRI for the evaluation of hemato-oncological diseases with lower extremity manifestations
Show more Molecular Imaging: Non-radioactive/Multimodal Imaging: Clinical Applications of Non-radioactive/Multimodal Imaging

Molecular Imaging: Non-radioactive/Multimodal Imaging

  • Effectiveness of an image response assessment team (IRAT) approach to advance imaging biomarker inclusion in cancer therapy trials
  • Simultaneous PET/MRI for the evaluation of hemato-oncological diseases with lower extremity manifestations
Show more Molecular Imaging: Non-radioactive/Multimodal Imaging

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire